Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsDalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewDalbavancin: a novel antimicrobialUniDrug-target: a computational tool to identify unique drug targets in pathogenic bacteriaA focus on intra-abdominal infections.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusUse of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Mutations in mmpL and in the cell wall stress stimulon contribute to resistance to oxadiazole antibiotics in methicillin-resistant Staphylococcus aureusInvestigational antimicrobial agents of 2013.Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771.Iclaprim.Current and novel antibiotics against resistant Gram-positive bacteriaIn vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Cephalosporins in clinical development.Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strainStaphylococcus aureus with reduced susceptibility to vancomycin.Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.Tigecycline: a new glycylcycline for treatment of serious infections.Anti-MRSA agents: under investigation, in the exploratory phase and clinically available.Therapeutic potential of peptide deformylase inhibitors.Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.Oritavancin--an investigational glycopeptide antibiotic.Update on daptomycin: the first approved lipopeptide antibiotic.Generation of ramoplanin-resistant Staphylococcus aureus.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.Review of dalbavancin, a novel semisynthetic lipoglycopeptide.Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Effect of membrane composition on antimicrobial peptides aurein 2.2 and 2.3 from Australian southern bell frogsAcquired vancomycin resistance in clinically relevant pathogens.Vancomycin resistance: are there better glycopeptides coming?
P2860
Q24646677-6959DFDD-095C-4D5B-93A0-9776820C47EFQ24647429-C3D94367-2F06-431B-9DC3-35A66F8D4BFAQ24674841-321AEF24-049F-4A20-BC9A-D53378B35587Q28481491-8559FF07-BE48-4F15-844B-531E0F1703E7Q33763449-A2239F14-105E-4966-A874-8B886172A4ADQ33935282-DB807732-777A-4689-BC5E-49FD6AE438BEQ34123752-9AC42832-CB7C-44C5-BDB0-7B5F830AD8ABQ34157657-12D9C78A-65E1-4947-A9F4-8CFF0E88A4E7Q34298926-4553084F-48F3-46DE-84E0-22B2540ACACEQ34375204-67D38A2D-FCD5-40B5-9142-27CE12A3BC60Q34571545-396AD0B8-1EE4-4F8C-9C21-8F123FE8A1FAQ34666376-E1FE74C6-92D3-4C2D-885A-DF35B3563E4BQ35026521-1071733A-56C2-4B6C-826C-2C60D0606D95Q35065908-381BA35E-7506-452B-A12B-A18A63013B01Q35166807-C6A61DFB-8C48-49A6-B3BF-7569AFF319CFQ35806369-8747434B-880E-463C-8360-95DCD936179DQ35842532-A4E6EA82-08D0-4084-BF11-F64820838DBCQ35879071-C66AB8E5-3D1B-440D-8889-5EA8DED6736DQ35882353-295CEB6B-6B8F-4841-BD98-8D056B9D5DBBQ36188333-B670F322-A199-416D-8059-D34BDD3BC781Q36218312-85C0F859-0DA6-490C-B9AA-25801862998AQ36233502-F5A1A46C-37C0-437A-86DA-6C5FDEEA82ACQ36249883-607824F2-121D-4BB5-8B76-1E2CDC60D98EQ36328966-9F857115-E818-48B1-890B-792F83A69E91Q36426011-23F14F29-C872-451A-B155-9E65AE3FD234Q36521880-DDC7736D-398D-4FAF-AC07-79985BCACEEDQ36680162-2DDDD03A-886F-4F99-9B81-DDD920916928Q36718474-D5CB076E-EC86-4A38-AFE4-37E5D02FB0EEQ36763997-F29381D7-4858-4674-B835-AE2D46CCE3A5Q36777821-73269598-DDDB-4F23-881B-E7803C3D8116Q36802632-D03A376A-14C4-4127-89D2-96290E8F6CE4Q36901937-722AD7CB-EC33-448D-AB0F-0240085C9F15Q36968150-8DBC063A-C623-4474-82B4-AB9E98304557Q37071199-033D8F0C-1A2A-43A0-B4F0-322181E813DEQ37119259-102486A7-CA98-4C42-A974-96BF8DD08F47Q37144800-7B177AEC-5007-466B-8D87-1192EC1D9880Q37174100-1A189980-EA46-471A-8D7A-72A676AD0A1CQ37277016-EF48719B-60AE-4CE9-99B0-38E0A1CBDCF3Q37277083-A1DC0AE6-3C9F-4890-A823-0AAA1591B83DQ37340562-8AFC61C6-96D3-4BA0-AB6F-7257F6A5F167
P2860
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@ast
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@en
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@nl
type
label
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@ast
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@en
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@nl
prefLabel
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@ast
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@en
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@nl
P2093
P356
P1476
Antibacterial susceptibility o ...... at the Hershey Medical Center.
@en
P2093
Bulent Bozdogan
Cynthia Whitener
Duygu Esel
Frederick A Browne
Peter C Appelbaum
P304
P356
10.1093/JAC/DKG457
P407
P577
2003-10-16T00:00:00Z